{"title":"Clinical advances in investigational epilepsy treatments.","authors":"Slobodan M Janković","doi":"10.1080/13543784.2025.2574992","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Although innovative ways of treating epilepsy that is resistant to standard therapy are actively being researched, not many have demonstrated sufficient efficacy and safety in clinical research to obtain marketing authorization.</p><p><strong>Areas covered: </strong>The article aims to provide a concise overview of the most important investigational treatments for epilepsy that have achieved breakthroughs in clinical studies in terms of efficacy and safety. Relevant studies published between 2020 and 2025 were searched for in PubMed and Google Scholar databases, without language restrictions.</p><p><strong>Expert opinion: </strong>Although the first clinical breakthroughs have been achieved in the causal therapy of epilepsy using cell therapy and antisense oligonucleotides, larger clinical and observational studies are needed after the wider application of these therapeutic methods to evaluate their true place in epilepsy therapy. Symptomatic antiseizure medication has achieved significantly greater success in clinical practice by acting through several different mechanisms, and in the future, the reduction of the number of patients who will not respond favorably to any form of antiseizure medication could be expected.</p>","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"1-7"},"PeriodicalIF":4.1000,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2574992","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Although innovative ways of treating epilepsy that is resistant to standard therapy are actively being researched, not many have demonstrated sufficient efficacy and safety in clinical research to obtain marketing authorization.
Areas covered: The article aims to provide a concise overview of the most important investigational treatments for epilepsy that have achieved breakthroughs in clinical studies in terms of efficacy and safety. Relevant studies published between 2020 and 2025 were searched for in PubMed and Google Scholar databases, without language restrictions.
Expert opinion: Although the first clinical breakthroughs have been achieved in the causal therapy of epilepsy using cell therapy and antisense oligonucleotides, larger clinical and observational studies are needed after the wider application of these therapeutic methods to evaluate their true place in epilepsy therapy. Symptomatic antiseizure medication has achieved significantly greater success in clinical practice by acting through several different mechanisms, and in the future, the reduction of the number of patients who will not respond favorably to any form of antiseizure medication could be expected.
期刊介绍:
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.